glp-1 discontinuation rates Patients with diabetes who remained on drugs had lower cardiovascular risk Reasons for discontinuation of GLP1

At 24 months, 17.8 kg reduction from baseline (99.5 kg to 81.7 kg), BMI reduced by 5.5 kg/m (from 36.5 to 31.0 kg/m), maintaining 20.6% 3.2% weight loss, though 95% attrition limits clinical interpretability

Does it stunt growth? These fears may keep people from starting isotretinoin, even when the treatment is warranted, generally safe and could vastly improve their quality of life

Oncotarget 7 , 4146041472 (2016)

Tirzepatide produces 20.9% mean body weight reduction at 72 weeks in Phase 3 trials, driven by appetite suppression and insulin sensitization

Contact us for this or any other water treatment needs.

This product is not intended for use in children